Mal-ID maps disease-associated immune-receptor patterns across infections and autoimmune conditions
Mal-ID analyzed B-cell and T-cell receptor repertoires from 593 people, including patients with COVID-19, HIV, systemic lupus erythematosus and type-1 diabetes, influenza-vaccination recipients and healthy controls. Its combined models classified held-out immune states and highlighted disease-associated receptor patterns; interpretation identified distinct autoreactivity features in lupus and type-1 diabetes and antigen-associated receptor sequences in COVID-19. The authors also evaluated classification on independent COVID-19 cohorts.
Technology: Mal-ID (MAchine Learning for Immunological Diagnosis), an ensemble using repertoire feature models and ESM-2 protein-language-model embeddings
Family ESM / ESMFold: profile · models page
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The authors also evaluated classification on independent COVID-19 cohorts.
- Still unknown: This is a patient-sample diagnostic-validation and immune-biology study, not evidence of clinical deployment or benefit. Validation cohorts and disease-specific sample sizes are limited; external COVID-19 classification involved small cohorts and thresholds were tuned in some analyses. Additional disease-specific validation, threshold calibration, sequencing-depth assessment and interpretation alongside standard clinical assessment remain necessary. Its 2024 bioRxiv preprint is the same work, not a separate finding.
- AI role: Three machine-learning representations of B-cell and T-cell receptor data were combined to classify immune states and prioritize disease-associated receptor sequences, gene segments and isotypes for biological interpretation.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/39977494/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 132 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.